GlassScriptPhysician profile
Estella A Esteban
NPI 1326493933
$1,640.64
in general payments reported to CMS, 2019-2025
16 companies · $184 in 2025
The $184 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,229 · 2022: $190 · 2024: $37.73 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $222.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $309.83 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $282.45 | 2021 | |
| Novocure INC. | $139.22 | 2021 | |
| Alexion Pharmaceuticals, INC. | $121.49 | 2021 | |
| Genzyme Corporation | $112.88 | 2021 | |
| Kestra Medical Technology Services, INC. | $109.36 | 2025 | Assure Wcd |
| Abbott Laboratories | $92.61 | 2021-2024 | Jot Dx |
| Celgene Corporation | $89.15 | 2021 | |
| Biodelivery Sciences International, INC. | $76.42 | 2021 | |
| Boston Scientific Corporation | $74.93 | 2025 | General - Therapies |
| Redhill Biopharma INC. | $70.50 | 2021 | |
| Emergent Biosolutions INC. | $45.00 | 2021 | |
| Grt US Holding, INC. | $45.00 | 2021 | |
| Abbvie INC. | $35.79 | 2021 | |
| Baudax Bio INC. | $18.69 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $17.32 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Estella Esteban listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.